Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The efficacy and safety of ixekizumab was demonstrated regardless of previous treatment with a biologic. Ixekizumab was efficacious in systemic treatment-naive, biologic-naive, biologic/anti-TNF-exposed and biologic/anti-TNF-failure patients.1
An analysis of patients with prior use of non-biologic systemic therapies (including methotrexate, cyclosporine, retinoids, and psoralen/ultraviolet therapy) concluded that ixekizumab was effective irrespective of prior exposure to non-biologic systemic agents.2
Prior Biologic and Non-Biologic Systemic Therapy Use in the Pivotal Phase 3 Psoriasis Studies
Note that different dosing regimens, including unapproved doses, are included in this response. Please refer to the Taltz summary of product characteristics for approved dosing.1
Examination of the presence or absence of previous treatment with a biologic did not identify a difference in response at week 12 of the pivotal phase 3 UNCOVER clinical trials.3
Across 3 multicenter, randomized, double-blind, placebo-controlled trials (UNCOVER-1, -2, and -3), 26% of patients had received prior biologic therapy for the treatment of psoriasis.4 Of these,
15% had received at least 1 anti-TNF alpha agent, and
9% had received an anti-IL-12/IL-23.3
Previous biologics received in over 5% of patients in UNCOVER-1 were
etanercept (range 17%-20% across treatment arms)
ustekinumab (12%-13%), and
Previous biologics received in UNCOVER-2 and -3 included
adalimumab (range 5%-10% across treatment arms)
ustekinumab (5%-10%), and
Patients were excluded from the 3 pivotal trials if they had previously received IL-17 antagonists. Patients with prior use of etanercept were excluded from UNCOVER-2 and -3.7
Patients were required to undergo a washout period with the range of 3 to 6 half-lives of any previous biologic agent prior to study baseline.7
Ixekizumab Efficacy Stratified by Previous Biologic Use
Patient reported reasons for stopping previous biologics prior to entering the UNCOVER trials were collected, but not systematically defined. Therefore, data on efficacy or safety of ixekizumab after patient exposure to a previous biologic therapy is not stratified by reason for stopping prior biologics.
UNCOVER-2 and -3 Pooled Secondary Analysis at Week 12
Figure 1. Pooled UNCOVER-2 and -3: PASI Response Rates Stratified by Previous Biologic Use at Week 12, NRI10
Abbreviations: Bio = biologic; ETN = etanercept; IXE = ixekizumab; NRI = nonresponder imputation; PASI = Psoriasis Area and Severity Index; Q2W = every 2 weeks; Q4W = every 4 weeks.
Note: p<.001 for all comparisons between IXE and ETN.
Table 1. Pooled UNCOVER-2 and -3: Median Time to PASI 90 and PASI 100 for Ixekizumab Every 2 Week Dosing in Patients With vs Without Prior Exposure to Biologics11
Prior Biologic Use
Abbreviation: PASI = Psoriasis Area and Severity Index.
UNCOVER-1 Secondary Analysis at Week 60
Responders, those with sPGA (0,1), to ixekizumab in the 12-week induction period of UNCOVER-1 were re-randomized to ixekizumab Q4W or placebo. Figure 2 demonstrates that patients who received ixekizumab maintained high levels of efficacy at week 60 regardless of previous biologic use.5
Figure 2. UNCOVER-1: PASI Response Rates Stratified by Previous Biologic Use at Week 60, NRI5
Abbreviations: Bio = biologic; IXE = ixekizumab; NRI = nonresponder imputation; PASI = Psoriasis Area and Severity Index; PBO = placebo; Q4W = every 4 weeks; sPGA = static Physician Global Assessment.
Prior Etanercept Use in UNCOVER-3
Figure 3 depicts PASI 75, PASI 90, and PASI 100 responses to ixekizumab treatment in patients with previous etanercept use in UNCOVER-3. This analysis included only those patients switching to ixekizumab Q4W following an initial 12-week treatment period with etanercept and 4-week placebo washout period.12
Figure 3. UNCOVER-3: PASI Response Rates in Patients who Received Etanercept During the 12-Week Induction Period Followed by Ixekizumab Q4W During Open-Label Extension Period, NRI12
ETN = etanercept; IXE = ixekizumab; NRI = nonresponder imputation;
PASI = Psoriasis Area and Severity Index; PBO = placebo; Q4W = every
Note: Error bars=95% confidence intervals.
Previous Non-Biologic Systemic Therapy
An analysis of patients with prior use of non-biologic systemic therapies (including methotrexate, cyclosporine, retinoids, and psoralen/ultraviolet therapy) concluded that ixekizumab was effective irrespective of prior exposure to non-biologic systemic agents as shown in Figure 4.2
Figure 4. Pooled UNCOVER-1, -2, and -3: PASI Response Rates Stratified by Prior Non-biologic Treatment at Week 12, NRI2
ETN = etanercept; IXE Q2W = ixekizumab every 2 weeks; IXE Q4W =
ixekizumab every 4 weeks; NRI = nonresponder imputation; PASI =
Psoriasis Area and Severity Index; PBO = placebo.
NOTE: ETN data is from UNCOVER-2 and UNCOVER-3 only.
* p<.05 vs PBO.
ǂ p<.001 vs PBO (grey) and ETN (purple).
Ixekizumab Use in Secukinumab Non-Responders
An independent Canadian multicenter, retrospective study reviewed patients with moderate-to-severe plaque psoriasis previously treated with secukinumab 300 mg before beginning ixekizumab therapy.13
After 12 weeks of ixekizumab therapy, PASI 75 or PGA (0,1) was achieved in
15/17 (88.2%) of patients that met study criteria
4/4 (100%) secukinumab primary nonresponders
8/9 (88.9%) secukinumab secondary nonresponders, and
3/4 (75%) of patients who stopped secukinumab due to intolerance or non-drug related reasons.13
Duration of secukinumab therapy had no impact on ixekizumab efficacy outcomes.13
Additional independent retrospective reviews of ixekizumab efficacy following secukinumab therapy have been reported.13-17
2. Reich K, Menter A, Paul C, et al. Efficacy of ixekizumab in patients who have or have not received prior non-biologic systemic therapies: a pooled analysis of three phase 3 trials. Poster presented at: 5th International Congress of the Psoriasis International Network; July 7-9, 2016; Paris, France.
4. Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674-681. http://dx.doi.org/10.1111/bjd.16050
5. Gerdes S, Korman N, Wilhelm S, et al. Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at Weeks 12 and 60 from UNCOVER-1. Poster presented at: 24th Congress of the European Academy of Dermatology and Venereology; October 7-15, 2015; Copenhagen, Denmark.
6. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551. Supplementary Appendix. http://dx.doi.org/10.1016/S0140-6736(15)60125-8
7. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711
8. Gottlieb AB, Lacour JP, Korman N, Wilhelm S, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: An integrated analysis of two phase iii randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679-685. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412924/
9. Gottleib AB, Gerdes S, Lacour JP, et al. Ixekizumab in patients with moderate to severe psoriasis who have or have not received prior biologic therapies: an integrated analysis of 2 phase III studies. Poster presented at: 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. https://server.aad.org/eposters/Submissions/getFile.aspx?id=3428&type=sub
10. Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679-685. http://dx.doi.org/10.1111/jdv.13990
11. Pinter A, Langley R, See K, et al. Ixekizumab achieves rapid and high clearance in psoriasis patients with or without prior exposure to biologics. Poster presented at: 28th Annual Meeting of the European Academy of Dermatology and Venereology; October 9-13, 2019; Madrid, Spain.
12. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of ixekizumab in patients previously treated with etanercept. Poster presented at: 25th Congress of the European Academy of Dermatology and Venereology; September 28-October 2, 2016; Vienna, Austria.
13. Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155-157. http://dx.doi.org/10.1016/j.jaad.2018.01.003
14. Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis [abstract]. J Dermatolog Treat. 2019;30(3):216-220. http://dx.doi.org/10.1080/09546634.2018.1506081
15. Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547-1548. http://dx.doi.org/10.1111/bjd.17580
16. Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol. 2019;33(9):e338-e341. http://dx.doi.org/10.1111/jdv.15630
17. Sherman S, Cohen ES, Amitay-Laish I, et al. IL-17a inhibitor switching - efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol. 2019;99(9):769-773. http://dx.doi.org/10.2340/00015555-3200
IL = interleukin
IL-17 = interleukin-17
PGA = Physician Global Assessment
PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index
PASI 90 = 90% improvement from baseline in Psoriasis Area and Severity Index
PASI 100 = 100% improvement from baseline in Psoriasis Area and Severity Index
Q2W = every 2 weeks
Q4W = every 4 weeks
sPGA = static Physician Global Assessment
TNF = tumor necrosis factor
Datum fӧr senaste ӧversyn 2019 M09 18